fig8

Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy

Figure 8. Plasma levels of liposomal drugs at 1 and 24 h after intravenous administration. A: drug plasma levels after single administration or co-administration of PL-MLP and PLD in BALB/c. No change in drug levels at 24 h, indicating no pharmacokinetic interference between PL-MLP and PLD under the experimental conditions; B: comparison of drug plasma levels 24 h after injection of PLAD-MLP, PL-MLP, PLD, or PL-MLP+PLD. There is a major (> 2-fold) increase of MLP levels when drugs are co-encapsulated in PLAD-MLP, but no change of Dox levels, as compared to single liposome (PL-MLP) or combined liposomes (PL-MLP+PLD) co-administration

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/